Now Playing
News|Videos|September 29, 2023
Coming Soon: Evolving Strategies for Treating Metastatic Non-Small Cell Lung Cancer: Focus on TROP2-Directed ADCs
Author(s)Anne S. Tsao, MD
Expert oncologist Anne Tsao, MD, shares her excitement for an upcoming precision medicine program focused on the evolving role of TROP2-directed antibody drug conjugates in metastatic non-small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
4
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
5